A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...

Some 20 weeks after stopping their drugs, the participants in the studies had put back on an average of 2.5 kilograms (5.5 ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks.

Those projections of reduced spending were reflected in a survey released in December by data analytics firm Numerator that ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental ...

The age-old advice to lose weight is to exercise and eat healthy, but what if you can’t work out regularly (or just don’t ...

The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...